Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects

1 Sept 2016

Abstract excerpt

The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress c-Myc expression, and were initially shown to have efficacy in a number of c-Myc-dependent hematologic malignancies. Recent studies have now revealed a broader role for BET inhibitors in hematologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27729803
DOI: 10.2147/ott.s100515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsPMID 27729803Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

BET inhibitors as novel therapeutic agents in breast cancerSemantic proximity Read ↗

Targeting MYC dependence in cancer by inhibiting BET bromodomainsSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.